Payment overview · 2025
General Payments
$1,521.77
30 reported records · 9 companies
Healthcare provider profile · identity verified
Douglas Wayne Brant, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BETHANY, OK · NPI 1780618108
Verified facts
What the public records show
CMS Open Payments records show Douglas Wayne Brant, M.D. received $1,521.77 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $424.28 | 27.9% | 7 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $262.22 | 17.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $196.37 | 12.9% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $153.57 | 10.1% | 4 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $124.48 | 8.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $117.36 | 7.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $115.78 | 7.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $109.62 | 7.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.09 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,516.77 | 29 |
| Education | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $282.64 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $196.37 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $153.57 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $141.64 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $131.87 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $130.35 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $124.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $117.36 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $115.78 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $109.62 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.54 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 652 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 93 |
| Gabapentin | Gabapentin | 357 | 66 |
| Furosemide | Furosemide | 285 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 82 |
| Omeprazole | Omeprazole | 176 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 56 |
| Metformin Hcl Er | Metformin Hcl | 167 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 49 |
| Lisinopril | Lisinopril | 165 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 165 | 42 |
| Oxycodone Hcl | Oxycodone Hcl | 164 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 164 | 20 |
| Tramadol Hcl | Tramadol Hcl | 157 | 33 |
| Montelukast Sodium | Montelukast Sodium | 156 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 32 |
| Ezetimibe | Ezetimibe | 135 | 55 |
| Alprazolam | Alprazolam | 130 | 25 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 119 | 16 |
| Memantine Hcl | Memantine Hcl | 115 | 31 |
| Trazodone Hcl | Trazodone Hcl | 115 | 27 |
| Prednisone | Prednisone | 111 | 43 |
| Eliquis | Apixaban | 107 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 19 |
| Potassium Chloride | Potassium Chloride | 101 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 58 |
| Donepezil Hcl | Donepezil Hcl | 99 | 28 |
| Cephalexin | Cephalexin | 95 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 26 |
| Spironolactone | Spironolactone | 91 | 34 |
| Pregabalin | Pregabalin | 89 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 23 |
| Ibuprofen | Ibuprofen | 86 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 24 |
| Celecoxib | Celecoxib | 81 | 26 |
| Ondansetron Odt | Ondansetron | 81 | 30 |
| Trulicity | Dulaglutide | 81 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 28 |
| Azelastine Hcl | Azelastine Hcl | 77 | 33 |
| Clonidine Hcl | Clonidine Hcl | 76 | 22 |
| Carvedilol | Carvedilol | 72 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 19 |
| Famotidine | Famotidine | 70 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 69 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 64 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 20 |
| Meloxicam | Meloxicam | 63 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 19 |
| Morphine Sulfate | Morphine Sulfate | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 14 |
| Promethazine Hcl | Promethazine Hcl | 54 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | 17 |
| Amoxicillin | Amoxicillin | 51 | 31 |
| Bupropion Xl | Bupropion Hcl | 51 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 48 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 26 |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 45 | 14 |
| Lamotrigine | Lamotrigine | 45 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 16 |
| Mupirocin | Mupirocin | 44 | 16 |
| Farxiga | Dapagliflozin Propanediol | 43 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 19 |
| Finasteride | Finasteride | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Metformin Hcl | Metformin Hcl | 37 | 11 |
| Pentoxifylline | Pentoxifylline | 37 | 13 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 12 |
| Doxepin Hcl | Doxepin Hcl | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 20 |
| Simvastatin | Simvastatin | 33 | 12 |
| Linzess | Linaclotide | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 12 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Colesevelam Hcl | Colesevelam Hcl | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | 11 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 14 |
| Gentamicin Sulfate | Gentamicin Sulfate | 24 | 13 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Losartan Potassium | Losartan Potassium | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Niacin Er | Niacin | 19 | suppressed |
| Fanapt | Iloperidone | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 13 |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Nystatin | Nystatin | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,521.77 · 30 records | AstraZeneca Pharmaceuticals LP | AUSTEDO XR, BREZTRI, CAPLYTA, FARXIGA, GVOKE HYPOPEN, Kerendia, OTEZLA, Ozempic, RECORLEV, REPATHA, Veozah, Xhance | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error